Equities

Sanofi SA

0O59:LSE

Sanofi SA

  • Price (EUR)80.44
  • Today's Change-0.45 / -0.56%
  • Shares traded1.68m
  • 1 Year change-22.49%
  • Beta0.6161
Data delayed at least 20 minutes, as of Feb 06 2026 14:56 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

  • Revenue in EUR (TTM)--
  • Net income in EUR--
  • Incorporated1994
  • Employees84.59k
  • Location
    Sanofi SA46 Avenue de la Grande ArmeePARIS 75017FranceFRA
  • Phone+33 153774000Fax+33 153774463
  • Websitehttps://www.sanofi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0O59:LSE since
announced		Transaction
value
Ocular Therapeutix IncRumoured15 Jan 202615 Jan 2026Rumoured-2.56%--
Dynavax Technologies CorpAnnounced24 Dec 202524 Dec 2025Announced-2.17%1.87bn
Blueprint Medicines CorpDeal completed02 Jun 202502 Jun 2025Deal completed-8.10%9.10bn
Vigil Neuroscience IncDeal completed21 May 202521 May 2025Deal completed-13.99%466.72m
Data delayed at least 20 minutes, as of Feb 06 2026 14:56 GMT.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.